Identifying and producing low cost molecular binders based on naturally occurring human protein.
Uses two technology platforms to identify and produce low cost molecular binders based on naturally occurring human proteins. In addition, Borean develops a proprietary technology that enables multimerization of therapeutic proteins. Borean's lead product is a trimeric Apoliprotein A1 undergoing preclinical trials for plaque reduction in atherosclerosis. Borean also has further research programmes in Crohn's disease, HIV and cancer.
Sale of assets to Roche in 2006.
- Industry Biotech
- History M&A